Favrille initiates trial of lymphoma treatment

The current participant numbers represent approximately 65% of the 342 patients required to be enrolled in the trial. As originally projected, the company expects to complete enrollment on schedule by the end of the year. The study will evaluate the efficacy of FavId in combination with Rituxan treatment.

“We are very excited to report the status of patient enrollment in our phase III trial,” said Dr John Longenecker, president and CEO of Favrille. “We believe that the rapid enrollment rate, 65% in the first 10 months, is an indication of investigators’ and patients’ enthusiasm for this all-biologic treatment for NHL which avoids the side effects of chemotherapy and adds an active immunotherapy component to the known benefits of Rituxan.”

The FavId vaccine is based upon unique genetic information extracted from a patient’s tumor. FavId is currently under investigation in a pivotal phase III clinical trial for patients with follicular B-cell NHL and phase II clinical trials in other B-cell NHL indications. Favrille is developing additional applications based on its immunotherapy expertise and proprietary manufacturing technology, including a second product candidate, FAV-201, for the treatment of T-cell lymphoma.